CYBNCYBIN INC.

NYSE cybin.com


$ 0.21 $ 0.00 (-1.04 %)    

Monday, 09-Sep-2024 09:51:22 EDT
QQQ $ 454.39 $ 1.86 (0.41 %)
DIA $ 407.42 $ 0.09 (0.02 %)
SPY $ 545.27 $ 0.60 (0.11 %)
TLT $ 99.47 $ 0.09 (0.09 %)
GLD $ 231.00 $ -0.26 (-0.11 %)
$ 0.2102
$ 0.21
$ 0.21 x 1,500
-- x --
$ 0.21 - $ 0.21
$ 0.17 - $ 0.74
3,756,815
na
159.76M
$ 0.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 leadership-shake-ups-in-cannabis-and-psychedelics-marylands-cannabis-chief-resigns-costly-legal-battle-in-ma-drags-on--more

Maryland transitioned to an adult-use cannabis market a little over a year ago. Led by the state's Cannabis Administration ...

 hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

 cybin-continues-to-expect-to-commence-phase-3-pivotal-program-in-late-summer-it-had-type-b-initial-breakthrough-therapy-meeting-with-fda-late-last-week

Doug Drysdale, Chief Executive Officer of Cybin, said, "Having selected 30 clinical sites across the United States and Euro...

 cantor-fitzgerald-reiterates-overweight-on-cybin

Cantor Fitzgerald analyst Charles Duncan reiterates Cybin (AMEX:CYBN) with a Overweight.

 hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

Core News & Articles

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

 biopharma-co-cybin-reports-78m-loss-amid-accelerating-expansion-in-psychedelic-therapies-drug-development

Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now!

 cantor-fitzgerald-reiterates-overweight-on-cybin

Cantor Fitzgerald analyst Charles Duncan reiterates Cybin (AMEX:CYBN) with a Overweight.

 latest-executive-cannabis-changes-you-should-know-about-curaleaf-planet-13-elect-directors-and-more

As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through...

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...

 hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

Core News & Articles

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

 cybin-provides-corporate-update-and-highlights-upcoming-clinical-milestones-initiation-of-pivotal-cyb003-phase-3-study-in-mdd-expected-in-mid-2024-phase-2-topline-efficacy-and-safety-results-for-cyb004-in-generalized-anxiety-disorder-expected-q4-2024

- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports adva...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION